Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

3.92
+0.07001.82%
Post-market: 3.940.0200+0.51%19:38 EDT
Volume:2.13M
Turnover:8.34M
Market Cap:407.68M
PE:-2.04
High:4.07
Open:3.91
Low:3.85
Close:3.85
52wk High:6.42
52wk Low:2.72
Shares:104.00M
Float Shares:57.54M
Volume Ratio:2.68
T/O Rate:3.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9258
EPS(LYR):-2.2711
ROE:-139.63%
ROA:-70.96%
PB:3.20
PE(LYR):-1.73

Loading ...

Larimar Therapeutics to Host Investor Webcast on Nomlabofusp Program for Friedreich’s Ataxia

Reuters
·
Jun 27

U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys

Reuters
·
May 27

Larimar Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $9

THOMSON REUTERS
·
May 27

Larimar Therapeutics shareholders approve increase in authorized common shares to 215 million

Reuters
·
May 20

Exploring US High Growth Tech Stocks This May 2026

Simply Wall St.
·
May 15

Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall

Reuters
·
May 14

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million

Reuters
·
May 14

Larimar Therapeutics Q1 EPS USD -0.31

THOMSON REUTERS
·
May 14

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

THOMSON REUTERS
·
May 14

Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside

Dow Jones
·
May 06

Larimar study backs skin frataxin as surrogate endpoint for nomlabofusp trials

Reuters
·
May 01

Larimar Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
Apr 24

Larimar Therapeutics announces annual stockholder meeting

Reuters
·
Apr 11

Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR

TIPRANKS
·
Apr 01

Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 23

Larimar Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
Mar 20

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
Mar 20

Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million

Reuters
·
Mar 19

BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million

Reuters
·
Mar 19

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 19